A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

* 18 years old at time of consent * Diagnosed with a solid tumor that has progressed despite standard therapy or for which no standard effective or curative options exist or are suitable * EGFR-positive tumor expression * Adequate blood and organ function * Must agree to use contraception while on study and for 12 weeks after the last dose of IMGN289 as applicable * Must be willing and able to sign informed consent and follow the study schedule and other protocol requirements

* Other anti-cancer treatment during the study * Symptomatic brain metastases * Other clinically significant disease as defined by the protocol * Chronic skin condition that requires prescribed oral or intravenous treatment * History of severe rash that required discontinuation of prior EGFR targeted therapy * Receiving therapeutic doses of warfarin or heparin for anti-coagulation * Known diagnosis of HIV or active viral hepatitis * Women who are pregnant or breast feeding